Brought to you by 
Boston Biomedica spins out Panacos, gets $3mm in funding
26 Jan 2001
Executive Summary
Boston Biomedica has spun out its drug discovery and therapeutics arm, Panacos Pharmaceuticals. Investors AM Pappas & Associates and Ampersand Ventures paid $3mm in cash for 2.7mm shares of Panacos' Series B preferred stock, which represents 54.7% of the company.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Financing
- Private Placement
- Spin-Off
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Boston Biomedica spins out Panacos, gets $3mm in funding
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice